


**Amendments to the Claims:**

This listing of claims will replace all prior version, and listings, of claims in the application.

**Listing of Claims:**

Claims 1-3 (cancelled)  
Claims 4-15 (previously cancelled)  
Claim 16 (cancelled)  
Claims 17-32 (previously cancelled)  
Claims 33-35 (cancelled)  
Claims 36-42 (previously cancelled)  
Claim 43 (cancelled)  
Claims 44-52 (previously cancelled)  
Claims 53-63 (cancelled)

Claim 64. (New) A compound having the structure:



wherein  $R_1$  is independently H, F, Cl, Br, -CN, -OH, -NO<sub>2</sub>, -NR<sub>5</sub>R<sub>6</sub>, -SO<sub>2</sub>R<sub>5</sub>, -(CH<sub>2</sub>)<sub>n</sub>OR<sub>5</sub>, -(CH<sub>2</sub>)<sub>n</sub>CONR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>n</sub>NR<sub>5</sub>COR<sub>5</sub>, perfluoroalkyl, polyfluoroalkyl, aminoalkyl, or straight chained or branched C<sub>1</sub>-C<sub>7</sub> alkyl;


wherein  $R_5$  is independently H; or straight chained or branched  $C_1$ - $C_7$  alkyl;

wherein  $R_6$  is independently H; or straight chained or branched  $C_1$ - $C_7$  alkyl;

wherein each  $n$  independently is an integer from 0 to 6 inclusive;

wherein  $R_7$  is independently straight chained or branched  $C_1$ - $C_7$  alkyl;


wherein  $R_8$  is



wherein  $R_9$  is independently H; or straight chained or branched  $C_1$ - $C_4$  alkyl;

wherein  $R_{10}$  is independently H; or straight chained or branched  $C_1$ - $C_4$  alkyl;

wherein  $R_{11}$  is



wherein  $R_{12}$  is H, straight chained or branched  $C_1$ - $C_7$  alkyl,  $-(CH_2)_uOR_{17}$ , or  $-O(CH_2)_uOR_{17}$ ;

wherein  $R_{13}$  is independently H;  $-(CH_2)_uOR_5$ ;  $-(CH_2)_tCONR_5R_6$ ;  $-(CH_2)_uNR_5COR_5$ ;  $-(CH_2)_tCOR_7$ ;  $-(CH_2)_tCO_2R_5$ ;  $-(CH_2)_uNR_5R_6$ ;  $-(CH_2)_uCN$ ; straight chained or branched  $C_1$ - $C_7$  alkyl;  $C_1$ - $C_7$  alkyl in which the  $C_2$ - $C_7$  atoms may be optionally substituted with one or more F or Cl;  $C_3$ - $C_7$  cycloalkyl- $C_1$ - $C_7$  alkyl; straight chained or branched  $C_2$ - $C_7$  alkenyl or alkynyl; or  $C_3$ - $C_7$  cycloalkyl; phenyl or  $C_1$ - $C_6$  phenylalkyl; wherein the phenyl or  $C_1$ - $C_6$  phenylalkyl may be

substituted with one or more of F, Cl, -CN, -NO<sub>2</sub>, -NR<sub>5</sub>R<sub>6</sub>, -SO<sub>2</sub>R<sub>5</sub>,  
-(CH<sub>2</sub>)<sub>n</sub>COR<sub>7</sub>, -(CH<sub>2</sub>)<sub>n</sub>OR<sub>5</sub>, -(CH<sub>2</sub>)<sub>n</sub>CONR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>n</sub>NR<sub>5</sub>COR<sub>5</sub>, -(CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sub>5</sub>,  
-(CH<sub>2</sub>)<sub>n</sub>SO<sub>2</sub>NR<sub>5</sub>R<sub>6</sub>, straight chained or branched C<sub>1</sub>-C<sub>7</sub> alkyl,  
perfluoroalkyl, polyfluoroalkyl, or aminoalkyl;

or R<sub>12</sub> and R<sub>13</sub> together with the amide linkage to which they are  
attached are pyrrolidinonyl, piperidonyl or oxazolidinonyl;

wherein R<sub>14</sub> is H; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkyl; F; or  
-(CH<sub>2</sub>)<sub>r</sub>OR<sub>5</sub>;

wherein R<sub>15</sub> is H, straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkyl, or F;

with the proviso that when R<sub>14</sub> is -OH, R<sub>15</sub> cannot be F;

wherein R<sub>16</sub> is perfluoroalkyl, unsubstituted straight chained or  
branched C<sub>1</sub>-C<sub>7</sub> alkyl, substituted straight chained or branched C<sub>2</sub>-  
C<sub>7</sub> alkyl, wherein the C<sub>2</sub>-C<sub>7</sub> alkyl may be substituted with one or  
more of F, Cl, -CN, -SO<sub>2</sub>R<sub>5</sub>, -(CH<sub>2</sub>)<sub>n</sub>COR<sub>7</sub>, -(CH<sub>2</sub>)<sub>n</sub>OR<sub>5</sub>, -(CH<sub>2</sub>)<sub>n</sub>CONR<sub>5</sub>R<sub>6</sub>,  
-(CH<sub>2</sub>)<sub>n</sub>NR<sub>5</sub>COR<sub>5</sub>, -(CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sub>5</sub>, -(CH<sub>2</sub>)<sub>n</sub>OCF<sub>3</sub>, perfluoroalkyl,  
polyfluoroalkyl, or aminoalkyl, straight chained or branched C<sub>2</sub>-  
C<sub>7</sub> alkenyl or alkynyl, or C<sub>3</sub>-C<sub>7</sub> cycloalkyl or cycloalkenyl;  
phenyl, heteroaryl, or C<sub>1</sub>-C<sub>7</sub> phenylalkyl, wherein the phenyl,  
heteroaryl, or C<sub>1</sub>-C<sub>7</sub> phenylalkyl may be substituted with one or  
more of F, Cl, Br, -CN, -NO<sub>2</sub>, -NR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>n</sub>NR<sub>5</sub>COR<sub>5</sub>, -SO<sub>2</sub>R<sub>5</sub>,  
-(CH<sub>2</sub>)<sub>n</sub>COR<sub>7</sub>, -(CH<sub>2</sub>)<sub>n</sub>OR<sub>5</sub>, -(CH<sub>2</sub>)<sub>n</sub>CONR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sub>5</sub>, -(CH<sub>2</sub>)<sub>n</sub>SO<sub>2</sub>NR<sub>5</sub>R<sub>6</sub>,  
ethylenedioxy, methylenedioxy, straight chained or branched C<sub>1</sub>-C<sub>7</sub>  
alkyl, perfluoroalkyl, polyfluoroalkyl, or aminoalkyl, straight  
chained or branched C<sub>2</sub>-C<sub>7</sub> alkenyl or alkynyl, or C<sub>3</sub>-C<sub>7</sub> cycloalkyl  
or cycloalkenyl; quinolinyl, 1-naphthyl, 2-naphthyl, or 2,1,3-  
benzothiadiazolyl; wherein the quinolinyl, 1-naphthyl, 2-naphthyl,  
or 2,1,3-benzothiadiazolyl may be substituted with one or more  
of F, Cl, Br, -CN, -NO<sub>2</sub>, -NR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>n</sub>NR<sub>5</sub>COR<sub>5</sub>, -SO<sub>2</sub>R<sub>5</sub>, -(CH<sub>2</sub>)<sub>n</sub>COR<sub>7</sub>,  
-(CH<sub>2</sub>)<sub>n</sub>OR<sub>5</sub>, -(CH<sub>2</sub>)<sub>n</sub>CONR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sub>5</sub>, -(CH<sub>2</sub>)<sub>n</sub>SO<sub>2</sub>NR<sub>5</sub>R<sub>6</sub>,

ethylenedioxy, methylenedioxy, straight chained or branched C<sub>1</sub>-C<sub>7</sub> alkyl, perfluoroalkyl, polyfluoroalkyl, or aminoalkyl;

with the proviso that when R<sub>8</sub> is NR<sub>9</sub>(R<sub>14</sub>R<sub>15</sub>)<sub>s</sub>NR<sub>10</sub>R<sub>11</sub>, R<sub>16</sub> cannot be quinolinyl;

wherein R<sub>17</sub> is H, straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkyl, perfluoroalkyl, or polyfluoroalkyl;

wherein each p independently is an integer from 0 to 2 inclusive;

wherein each r independently is an integer from 0 to 3 inclusive;

wherein each s independently is an integer from 1 to 6 inclusive;

wherein t is an integer from 1 to 4 inclusive; and


wherein each u independently is an integer from 2 to 4 inclusive;

or a pharmaceutically acceptable salt thereof.


65. (New) The compound of claim 64, wherein R<sub>1</sub> is independently H, F, Cl or Br;

wherein R<sub>16</sub> is unsubstituted straight chained or branched C<sub>1</sub>-C<sub>7</sub> alkyl, phenyl, heteroaryl, or C<sub>1</sub>-C<sub>7</sub> phenylalkyl, wherein the phenyl, heteroaryl, or C<sub>1</sub>-C<sub>7</sub> phenylalkyl may be substituted with one or more of F, Cl, Br, -CN, -NO<sub>2</sub>, -NR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>n</sub>NR<sub>5</sub>COR<sub>5</sub>, -SO<sub>2</sub>R<sub>5</sub>, -(CH<sub>2</sub>)<sub>n</sub>COR<sub>7</sub>, -(CH<sub>2</sub>)<sub>n</sub>OR<sub>5</sub>, -(CH<sub>2</sub>)<sub>n</sub>CONR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sub>5</sub> and -(CH<sub>2</sub>)<sub>n</sub>SO<sub>2</sub>NR<sub>5</sub>R<sub>6</sub>; and p is 1.


66. (New) The compound of claim 65, wherein R<sub>8</sub> is




67. (New) The compound of claim 66, wherein the compound is




68. (New) The compound of claim 65, wherein  $R_8$  is




69. (New) The compound of claim 68, wherein the compound is selected from the group consisting of:



70. (New) The compound of claim 65, wherein  $R_8$  is



71. (New) The compound of claim 70, wherein the compound is selected from the group consisting of:



72. (New) The compound of claim 64, wherein the compound is the (+) enantiomer.

73. (New) The compound of claim 64, wherein the compound is the (-) enantiomer.

74. (New) A pharmaceutical composition comprising a

therapeutically effective amount of the compound of claim 64 and a pharmaceutically acceptable carrier.

75. (New) The pharmaceutical composition of claim 64, wherein the amount of the compound is an amount from about 0.01mg to about 800mg.

76. (New) The pharmaceutical composition of claim 75, wherein the amount of the compound is an amount from about 0.01mg to about 500mg.

77. (New) The pharmaceutical composition of claim 76, wherein the amount of the compound is an amount from about 0.01mg to about 250mg.

78. (New) The pharmaceutical composition of claim 77, wherein the amount of the compound is an amount from about 0.1mg to about 60mg.

79. (New) The pharmaceutical composition of claim 78, wherein the amount of the compound is an amount from about 1mg to about 20mg.

80. (New) The pharmaceutical composition of claim 74, wherein the carrier is a liquid and the composition is a solution.

81. (New) The pharmaceutical composition of claim 74, wherein the carrier is a solid and the composition is a tablet.

82. (New) The pharmaceutical composition of claim 74, wherein the carrier is a gel and the composition is a suppository.

83. (New) A pharmaceutical composition made by combining a therapeutically effective amount of the compound of claim 64 and a pharmaceutically acceptable carrier.

84. (New) A process for making a pharmaceutical composition made by combining a therapeutically effective amount of the compound of claim 64 and a pharmaceutically acceptable carrier.

85. (New) Use of the compound of claim 64 for the preparation of a pharmaceutical composition for treating obesity.

86. (New) Use of the compound of claim 64 for the preparation of a pharmaceutical composition for treating depression.

87. (New) Use of the compound of claim 64 for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.

88. (New) Use of the compound of claim 64, wherein the abnormality is an eating disorder, obesity, bulimia nervosa, a sexual disorder, a reproductive disorder, depression, an epileptic seizure, hypertension, cerebral hemorrhage, congestive heart failure, or a sleep disturbance.